BACE1 Protein (AA 22-457) (His tag)

N° du produit ABIN7273904

Détail du produit

Antigène: BACE1 (Beta-secretase 1 (BACE1))

Type de proteíne: Recombinant

Attributs du protein: AA 22-457

Origine: Humain

Source: HEK-293 Cells

Purification/Conjugué: Cette BACE1 protéine est marqué à la His tag.

Fonction: Human BACE-1 Protein

Séquence: Thr22-Thr457

Attributs du produit: Recombinant Human BACE-1 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Thr22-Thr457.

Pureté: > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC

Stérilité: 0.22 μm filtered

niveau d'endotoxine: Less than 1EU per μg by the LAL method.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water.

Buffer: Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.

Stock: -20 °C,-80 °C

Stockage commentaire: -20 to -80°C for 12 months as supplied from date of receipt., -80°C for 3-6 months after reconstitution., 2-8°C for 2-7 days after reconstitution., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Date de péremption: 12 months

Détail du antigène

Antigène: BACE1 (Beta-secretase 1 (BACE1))

Autre désignation: BACE-1 (BACE1 Produits)

Synonymes: ASP2 Protein, BACE Protein, HSPC104 Protein, C76936 Protein, Bace Protein, MGC145931 Protein, BACE1 Protein, zgc:77409 Protein, beta-secretase 1 Protein, beta-site APP cleaving enzyme 1 Protein, beta-site APP-cleaving enzyme 1 Protein, BACE1 Protein, Bace1 Protein, bace1 Protein

Sujet: The beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1) initiates the generation of amyloid-β (Aβ), and the amyloid cascade leading to amyloid plaque deposition, neurodegeneration, and dementia in Alzheimer's disease (AD). Clinical failures of anti-Aβ therapies in dementia stages suggest that treatment has to start in the early, asymptomatic disease states.

Poids moléculaire: 49.5 kDa. Due to glycosylation, the protein migrates to 55-70 kDa based on Tris-Bis PAGE result.

NCBI Accession: NP_036236